Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder

Gene Expression Patterns

Volumn 1, Issue 1, 2001, Pages 17-21

  Kuromitsu, Junro ^a,b   Yokoi, Akira ^b   Kawai, Takatoshi ^b   Nagasu, Takeshi ^b   Aizawa, Takako ^a   Haga, Seiichi ^a   Ikeda, Kazuhiko ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Bipolar mood disorder; Brain; Disorders of the nervous system and aging; DNA array; DNA chip; Frontal lobe; Gene expression; Major depression; Neuropeptide Y; Neuropsychiatric disorders; Quantitative PCR; Schizophrenia; TaqMan PCR; Temporal lobe

Indexed keywords

EID: 0042287975     PISSN: 1567133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-133X(01)00003-5     Document Type: Article

References (6)

1. Caberlotto L., Hurd Y.L. Reduced neuropeptide Y mRNA expression in the prefrontal cortex of subjects with bipolar disorder. Neuroreport. 10:1999;1747-1750.
2. Gabriel S.M., Davidson M., Haroutunian V., Powchik P., Bierer L.M., Purohit D.P., Perl D.P., Davis K.L., Gabriel S.M., Davidson M., Haroutunian V., Powchik P., Bierer L.M., Purohit D.P., Perl D.P., Davis K.L. Neuropeptide deficits in schizophrenia vs. Alzheimer’s disease cerebral cortex. Biol. Psychiatry. 39:1996;82-91.
3. Lamm G.M., Nicol S.M., Fuller-Pace F.V., Lamond A.I. p72: A human nuclear DEAD box protein highly related to p68. Nucleic Acid Res. 24:1996;3739-3747.
4. Lie Y.S., Petropoulos C.J. Advances in quantitative PCR technology: 5′ nuclease assays. Curr. Opin. Biotechnol. 9:1998;43-48.
5. Lockhart D.J., Dong H., Byrne M.C., Follettie M.T., Gallo M.V., Chee M.S., Mittmann M., Wang C., Kobayashi M., Horton H., Brown E.L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nature Biotechnol. 14:1996;1675-1680.
6. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The Stanley Foundation brain collection and Neuropathology Consortium. Schizophr. Res. 44:2000;151-155.